WO2008081537A1 - Aromatic amino acid derivative with lat1 inhibitory activity, lat1 inhibitor containing the same and method for producing the same - Google Patents
Aromatic amino acid derivative with lat1 inhibitory activity, lat1 inhibitor containing the same and method for producing the same Download PDFInfo
- Publication number
- WO2008081537A1 WO2008081537A1 PCT/JP2006/326233 JP2006326233W WO2008081537A1 WO 2008081537 A1 WO2008081537 A1 WO 2008081537A1 JP 2006326233 W JP2006326233 W JP 2006326233W WO 2008081537 A1 WO2008081537 A1 WO 2008081537A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- same
- lat1
- inhibitory activity
- producing
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A useful and novel aromatic amino acid derivative which is soluble in water, has a selective inhibitory activity against LAT1 that is specifically expressed in a cancer cell, and has a high cancer cell growth inhibitory activity, an LAT1 inhibitor containing the same and a method for producing the same.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008551997A JPWO2008081537A1 (en) | 2006-12-28 | 2006-12-28 | Aromatic amino acid derivative having LAT1 inhibitory activity, LAT1 inhibitory activator containing the same and method for producing the same |
PCT/JP2006/326233 WO2008081537A1 (en) | 2006-12-28 | 2006-12-28 | Aromatic amino acid derivative with lat1 inhibitory activity, lat1 inhibitor containing the same and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/326233 WO2008081537A1 (en) | 2006-12-28 | 2006-12-28 | Aromatic amino acid derivative with lat1 inhibitory activity, lat1 inhibitor containing the same and method for producing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008081537A1 true WO2008081537A1 (en) | 2008-07-10 |
Family
ID=39588228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/326233 WO2008081537A1 (en) | 2006-12-28 | 2006-12-28 | Aromatic amino acid derivative with lat1 inhibitory activity, lat1 inhibitor containing the same and method for producing the same |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008081537A1 (en) |
WO (1) | WO2008081537A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011056916A1 (en) * | 2009-11-05 | 2011-05-12 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
JP2012163332A (en) * | 2011-01-28 | 2012-08-30 | J-Pharma Co Ltd | Kit for diagnosing malignancy of stomach cancer |
JP5470665B1 (en) * | 2013-08-20 | 2014-04-16 | ジェイファーマ株式会社 | Immunosuppressant |
WO2014112646A1 (en) | 2013-01-21 | 2014-07-24 | 国立大学法人大阪大学 | Phenoxyalkylamine compound |
WO2015173970A1 (en) * | 2014-05-15 | 2015-11-19 | ジェイファーマ株式会社 | Anti-malignant tumor agent composition |
WO2016103761A1 (en) * | 2014-12-22 | 2016-06-30 | ジェイファーマ株式会社 | Circulating biomarker for cancer |
JP2017155023A (en) * | 2016-03-04 | 2017-09-07 | ジェイファーマ株式会社 | Parenteral solution comprising aromatic amino acid derivative having lat1 inhibitory activity |
WO2019130637A1 (en) | 2017-12-28 | 2019-07-04 | ジェイファーマ株式会社 | Cancer therapeutic |
WO2020096041A1 (en) * | 2018-11-09 | 2020-05-14 | ジェイファーマ株式会社 | (s)-2-amino-3-{4-[(5-amino-2-phenylbenzo[d]oxazol-7-yl)methoxy]-3,5-dichlorophenyl}propanoic acid·monochloride, monohydrate thereof, crystal thereof, and method for producing same |
WO2021040042A1 (en) | 2019-08-30 | 2021-03-04 | ジェイファーマ株式会社 | Pharmaceutical composition for cancer treatment in patient having specific gene marker |
WO2021075585A1 (en) * | 2019-10-17 | 2021-04-22 | 学校法人 杏林学園 | Therapeutic agent for renal dysfunction |
CN112972391A (en) * | 2021-03-10 | 2021-06-18 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | bilirubin-JPH 203 nano-particles and preparation and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08325263A (en) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | New 2-amino-3-phenylpropionic acid derivative |
JP2000515133A (en) * | 1996-07-01 | 2000-11-14 | イーライ・リリー・アンド・カンパニー | Hypoglycemic and hypolipidemic compounds |
WO2003066574A1 (en) * | 2002-02-07 | 2003-08-14 | Hitoshi Endo | Aromatic amino acid derivatives and medicinal compositions |
-
2006
- 2006-12-28 JP JP2008551997A patent/JPWO2008081537A1/en active Pending
- 2006-12-28 WO PCT/JP2006/326233 patent/WO2008081537A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08325263A (en) * | 1995-05-31 | 1996-12-10 | Sumitomo Metal Ind Ltd | New 2-amino-3-phenylpropionic acid derivative |
JP2000515133A (en) * | 1996-07-01 | 2000-11-14 | イーライ・リリー・アンド・カンパニー | Hypoglycemic and hypolipidemic compounds |
WO2003066574A1 (en) * | 2002-02-07 | 2003-08-14 | Hitoshi Endo | Aromatic amino acid derivatives and medicinal compositions |
Non-Patent Citations (1)
Title |
---|
KANAI Y. ET AL.: "Amino acid transporter Yokusei ni yoru Koshuyo Koka no Kento", NIHON GAN GAKKAI GAKUJUTSU SOKAI KIJI, vol. 64TH, 15 August 2005 (2005-08-15), pages 312, XP003024475 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011056916A1 (en) * | 2009-11-05 | 2011-05-12 | Lexicon Pharmaceuticals, Inc. | Tryptophan hydroxylase inhibitors for the treatment of cancer |
JP2012163332A (en) * | 2011-01-28 | 2012-08-30 | J-Pharma Co Ltd | Kit for diagnosing malignancy of stomach cancer |
WO2014112646A1 (en) | 2013-01-21 | 2014-07-24 | 国立大学法人大阪大学 | Phenoxyalkylamine compound |
JP5470665B1 (en) * | 2013-08-20 | 2014-04-16 | ジェイファーマ株式会社 | Immunosuppressant |
WO2015173970A1 (en) * | 2014-05-15 | 2015-11-19 | ジェイファーマ株式会社 | Anti-malignant tumor agent composition |
JPWO2015173970A1 (en) * | 2014-05-15 | 2017-04-20 | ジェイファーマ株式会社 | Antineoplastic composition |
US10172835B2 (en) | 2014-05-15 | 2019-01-08 | J-Pharma Co., Ltd. | Anticancer agent composition |
WO2016103761A1 (en) * | 2014-12-22 | 2016-06-30 | ジェイファーマ株式会社 | Circulating biomarker for cancer |
CN105934672A (en) * | 2014-12-22 | 2016-09-07 | J制药股份有限公司 | circulating biomarker for cancer |
JPWO2016103761A1 (en) * | 2014-12-22 | 2017-11-02 | ジェイファーマ株式会社 | Cancer blood biomarkers |
JP2017155023A (en) * | 2016-03-04 | 2017-09-07 | ジェイファーマ株式会社 | Parenteral solution comprising aromatic amino acid derivative having lat1 inhibitory activity |
JP2020073586A (en) * | 2017-12-28 | 2020-05-14 | ジェイファーマ株式会社 | Cancer therapeutic agent |
EP3733175A4 (en) * | 2017-12-28 | 2021-08-18 | J-Pharma Co., Ltd. | Cancer therapeutic |
JP2019151672A (en) * | 2017-12-28 | 2019-09-12 | ジェイファーマ株式会社 | Cancer therapeutic agent |
WO2019130637A1 (en) | 2017-12-28 | 2019-07-04 | ジェイファーマ株式会社 | Cancer therapeutic |
KR102377742B1 (en) * | 2017-12-28 | 2022-03-22 | 제이 파마 가부시끼가이샤 | cancer treatment |
CN111491632A (en) * | 2017-12-28 | 2020-08-04 | J制药股份有限公司 | Cancer therapeutic agent |
KR20200101960A (en) | 2017-12-28 | 2020-08-28 | 제이 파마 가부시끼가이샤 | Cancer treatment |
JP6546367B1 (en) * | 2017-12-28 | 2019-07-17 | ジェイファーマ株式会社 | Cancer medicine |
JPWO2020096041A1 (en) * | 2018-11-09 | 2021-09-24 | ジェイファーマ株式会社 | (S) -2-Amino-3-{4-[(5-amino-2-phenylbenzo [d] oxazole-7-yl) methoxy] -3,5-dichlorophenyl} propanoic acid · 1 hydrochloride, part 1 Hydrate, its crystals and its manufacturing method |
WO2020096041A1 (en) * | 2018-11-09 | 2020-05-14 | ジェイファーマ株式会社 | (s)-2-amino-3-{4-[(5-amino-2-phenylbenzo[d]oxazol-7-yl)methoxy]-3,5-dichlorophenyl}propanoic acid·monochloride, monohydrate thereof, crystal thereof, and method for producing same |
JP2021038214A (en) * | 2019-08-30 | 2021-03-11 | ジェイファーマ株式会社 | Pharmaceutical composition for cancer treatment in patient having specific gene marker |
WO2021040043A1 (en) | 2019-08-30 | 2021-03-04 | ジェイファーマ株式会社 | Pharmaceutical composition used in patients having specific gene marker |
WO2021040042A1 (en) | 2019-08-30 | 2021-03-04 | ジェイファーマ株式会社 | Pharmaceutical composition for cancer treatment in patient having specific gene marker |
CN114340621A (en) * | 2019-08-30 | 2022-04-12 | J制药股份有限公司 | Pharmaceutical composition for patients with specific genetic markers |
CN114364381A (en) * | 2019-08-30 | 2022-04-15 | J制药股份有限公司 | Pharmaceutical composition for cancer treatment for patients with specific gene markers |
KR20220054312A (en) | 2019-08-30 | 2022-05-02 | 제이 파마 가부시끼가이샤 | Pharmaceutical composition for cancer treatment used for a patient having a specific genetic marker |
KR20220054603A (en) | 2019-08-30 | 2022-05-03 | 제이 파마 가부시끼가이샤 | Pharmaceutical composition for use in patients with specific genetic markers |
WO2021075585A1 (en) * | 2019-10-17 | 2021-04-22 | 学校法人 杏林学園 | Therapeutic agent for renal dysfunction |
CN112972391A (en) * | 2021-03-10 | 2021-06-18 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | bilirubin-JPH 203 nano-particles and preparation and application thereof |
CN112972391B (en) * | 2021-03-10 | 2022-06-21 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | bilirubin-JPH 203 nano-particles and preparation and application thereof |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008081537A1 (en) | 2010-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008081537A1 (en) | Aromatic amino acid derivative with lat1 inhibitory activity, lat1 inhibitor containing the same and method for producing the same | |
WO2007121252A3 (en) | Tandem photovoltaic cells | |
IL246494A0 (en) | Cell populations having immunoregulatory activity, method for isolation and uses | |
WO2008019871A3 (en) | Novel salts of the active substance rasagiline | |
WO2006088867A3 (en) | Method for expansion of stem cells | |
WO2011113798A3 (en) | Inhibitors of semicarabazide - sensitive amine oxidase | |
WO2006121542A8 (en) | Systems and methods for semantic knowledge assessment, instruction, and acquisition | |
WO2006044754A3 (en) | Process for preparing telmisartan | |
WO2007014373A3 (en) | Novel cells, compositions, and methods | |
WO2007008861A3 (en) | Methods of transferring photovoltaic cells | |
WO2006022664A3 (en) | Alanine 2, 3 aminomutases | |
GEP20135800B (en) | Method of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives preparation | |
WO2008086228A3 (en) | Arrays and methods for guided cell patterning | |
WO2007056083A3 (en) | Biosynthetic polypeptide fusion inhibitors | |
WO2006094945A3 (en) | Method for producing optically active alcohols by means of enzymatic reduction | |
EG25069A (en) | Process for urea production and related plant. | |
WO2007011665A3 (en) | Diffraction foils | |
EP2180276A4 (en) | Container freezing apparatus, and its manufacturing method | |
WO2007073937A3 (en) | Process for preparing crystalline forms of orlistat | |
WO2007010183A8 (en) | Data storage method | |
WO2010046419A3 (en) | Use of acetolactate synthase inhibitors on cultivated plants | |
WO2007098924A3 (en) | Composition comprising an agent for stabilizing active substances in drinking water, effervescent mixture, method for the production thereof, and use thereof | |
WO2008060792A3 (en) | Novel cells, compositions, and methods | |
PL1663997T3 (en) | 1h-azolyl-methyl-amides, method for the production thereof and use thereof as nitrification inhibitors | |
WO2009129205A3 (en) | Sparc anti-inflammatory activity and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06843611 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008551997 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06843611 Country of ref document: EP Kind code of ref document: A1 |